Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cytox Ltd.

This article was originally published in Start Up

Executive Summary

Cytox Ltd.'s diagnostics and research services are all based on the cell division cycle theory of Alzheimer's pathogenesis. The firm thinks its diagnostic, a blood test biomarker that measures the integrity of the cell cycle G1/S restriction point in peripheral blood lymphocytes, will detect AD in pre-symptomatic stages and that it can predict which patients suffering from mild cognitive impairment will convert to Alzheimer's. Furthermore, Cytox maintains that its lead program, a neuroblastoma assay, can screen compounds for their potential to affect Alzheimer's disease.

You may also be interested in...

Champions Biotechnology Inc.

Champions Biotechnology Inc.'s preclinical screening technology uses xenografts that it creates by implanting primary human cancer tumors into immune-deficient mice. The tumor cells are never passaged in cell tissue culture and therefore maintain the fundamental genotypic features of the original cancer because the risk of mutations through successive generations in culture is eliminated. The company has signed preclinical screening deals with a number of partners and it's also building its own therapeutic pipeline.

Rhenovia Pharma SAS

Rhenovia Pharma SAS believes it can help companies looking to improve existing Alzheimer's disease therapies by using computational models of the brain to identify chemical combinations capable of positively impacting disease symptoms. The start-up aims to build a service-based business running its specialized "biosimulations" on compounds that other companies currently market, have in development or have previously rejected for lack of efficacy.

Immuneering Corp.

Immuneering Corp. is developing mathematical models to predict whether a drug is likely to activate a patient's immune system to aid in fighting cancer and autoimmune diseases. The company's modeling application works with data from patient blood and tumor samples. Immuneering plans to offer its services to drug makers as a way of sorting patients into subpopulations, to understand the workarounds cancers develop against therapies, and to predict efficacy.

Related Content


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts